Centre for Drug Development: Strategy and portfolio

Our strategic priorities

Our ambition is to accelerate the delivery of the next generation of medicines to the patients who need them.

As the world's only charity-funded drug development facility, our strategy is uniquely focused by the drive for patient benefit. We are particularly interested in innovative projects, and our strengths are in:

  • First in class therapies
  • First in human clinical trials
  • Projects where we can use pharmacodynamic and stratification biomarker technologies to identify and progress new treatments which have the greatest potential for patient benefit

We maintain a broad portfolio across therapeutic modalities including antibodies, imaging agents, cell therapies, vaccines and targeted small molecules.

Our pipeline

PortfolioOur development portfolio contains 11 small molecule agents and 12 biologicals as of April 2017. Download the full pipeline or browse the agents below.

 

Agent

Target or technology

Partnerships

Indications

Status

BT1718

 

MT1-MMP

Bicycle Therapeutics

Solid, lung, sarcoma, breast

Exploratory

 

LY3143921

Cdc7

Lilly

Solid, colorectal, ovarian

 

Trial set up

AT13148

AGC, ROCK

Astex Therapeutics

Solid

Phase 1

Vandetanib/Selumetinib

EGFR, VEGFR, MEK

AstraZeneca

Solid, lung

Phase 1

AZD3965

MCT1

AstraZeneca

Solid, prostate, NHL, B-cell

Phase 1

AT9283

Aurora Kinase

Astex Therapeutics

Paediatric solid

Completed phase 1

Olaparib/Temozolomide

PARP1

AstraZeneca

Glioblastoma

Completed phase 1

AZD0424

Src-Abl

AstraZeneca

Solid

Completed phase 1

mIBG

NAT nor-adrenalin transporter

The Royal Marsden

Neuroblastoma

Phase 2

AMG319

p100d PI3K

Amgen

Head and neck oropharyngeal

Phase 2

Agent

Target or technology

Partnerships

Indications

Status

TYG100

 

Vaccine
G17, APC

TYG Oncology

Gastro-oesophageal, pancreatic

Exploratory

MEDI3039

Recombinant protein
TrailR2

MedImmune

 

Solid, colorectal, NSCLC

 

Exploratory

 

ATN658

Antibody
uPAR

Monopar Therapeutics

 

Solid, colon, breast, lung, melanoma

 

Exploratory

 

AST-VAC2

Vaccine
LAMP, hTERT

Asterias Biotherapeutics

Lung

Preclinical

BI-1206

Antibody
CD32b, FcγRIIB

BioInvent, Bloodwise

Lymphoma, B cell, CLL

Phase 1

MOv18

Antibody
α-folate R

King's College London

Solid

Phase 1

1RG CART

Cell therapy
GD2

Great Ormond Street Hospital for Children

Neuroblastoma

Phase 1

Dl-B4

Antibody
CD19

Merc Serono

Lymphoma, B cell, CLL

Completed phase 1

MVA-EBV1b

Vaccine
EBNA-LMP2

University of Birmingham

Nasopharyngeal, lymphoma

Completed phase 1

Our track record of marketed drugs

Abiraterone

Discovered at the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research, and developed by the Centre for Drug Development before licensing to Janssen Biotech, Abiraterone acetate (Zytiga®) is a hormonal therapy for prostate cancer.

Permetrexed

Permetrexed (Alimta®) is indicated for pleural mesothelioma and non-small cell lung cancer.

Temozolomide

One of our earliest successes, discovered by CRUK-funded scientists and developed by the CDD in the 1980s and 90s, Temozolomide (Temodal ®) is used worldwide as the frontline drug for glioblastoma and astrocytoma.

Etoposide phosphate

Etoposide phosphate (Etopophos®) is a drug used in small cell lung cancer and testicular tumours that no longer respond to other treatments.

Rucaparib

Discovered by CRUK-funded scientists at the Northern Institute for Cancer Research in a programme built on breakthroughs from CRUK's basic science, we progressed the early development of the PARP inhibitor Rucaparib (Rubraca®).

Formestane

Formestane (Lentaron®) is a selective aromatase inhibitor indicated in breast cancer.

Contact us

We are looking to partner with leading pharmaceutical and biotechnology companies and academic scientists who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Get in touch

Share this page